期刊文献+

重组人血管抑素生产菌培养基优化的研究

Optimization of Culture Medium for the Production of Recombinant Human Angiostatin
下载PDF
导出
摘要 用正交试验对血管抑素生产菌株E .colipQE32 AGN的发酵培养基成分进行了优化 ,优化后的合成培养基组成为 :无水葡萄糖 1% ,(NH4) 2 SO40 .4 % ,NaCl0 .2 % ,KH2 PO40 .3% ,K2 HPO42 % ,MgSO40 .0 1% ,盐酸硫胺素 0 .4mg/L ,核黄素 0 .1mg/L ,盐酸吡哆醇 0 .6mg/L ,D 泛酸 0 .3ml/L ,硫酸亚铁 30mg/L ,硫酸锂 30mg/L ,硫酸锰 2 5mg/L ,醋酸锌 2 0 mg/L ,硫酸铝 9mg/L ,优化后的生物量达到 9.0g/L以上 ,比采用LB培养基培养的生物量提高了一倍多。同时 ,优化培养基对工程菌目的蛋白的表达、溶解及复性未产生不利影响。 An efficient fermentation medium with high yields has been developed for the production of recombinant human angiostatin from pQE32-AGN. Orthogonal Design was applied to optimize the medium constituents. The optimal levels for the constituents were: glucose 1%,(NH 4) 2SO 4 0.4%,NaCl 0.2%,KH 2PO 4 0.3%,K 2HPO 4 2%,Mg SO 4 0.01%,VitaminB 1 0.4 mg/L, VitaminB 2 0.1 mg/L, VitaminB 6 0.6 mg/L, D-Pantothenic acid 0.3 ml/L,FeSO 4 30 mg/L,Li 2SO 4 30 mg/L, MnSO 4 25 mg/L, Zn(CH 3COO) 2 20 mg/L,Al 2(SO 4) 3 9 mg/L. The optimized medium produced 9.0 g/L biomass, which was twice more than LB medium. Moreover, the high-cell density growth of engineering strain has no side effect on the expression, dissolution, renaturation of target protein.
出处 《药物生物技术》 CAS CSCD 2004年第2期91-95,共5页 Pharmaceutical Biotechnology
基金 江苏省自然科学基金资助项目 (BK2 0 0 2 0 71)
关键词 血管抑素 大肠杆菌 高密度发酵 正交试验 复性 Angiostatin, Escherichia coli,High-cell density fermentation,Orthogonal Design,Renaturation
  • 相关文献

参考文献9

  • 1李民,陈常庆.重组大肠杆菌高密度发酵研究进展[J].生物工程进展,2000,20(2):26-31. 被引量:60
  • 2汪家政 等.蛋白质技术手册[M].科学出版社,2001..
  • 3Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning,A Laboratory Manual 2nd Ed, [M]. Cold Spring Habor Laboratory Press, New York, 1989.
  • 4Carmichael J, DeGraff W G, Gazdar A F, et al. Evaluation of a tetrazolium-basded semiautomated colorimetric assay:Assessment of chemosensitivity Testing [J]. Cancer Res,1987,47: 936.
  • 5Makrides S C. Strategies for achieving hlgh-level expression of genes in Escherichia coli [J]. Microbiological review,1996,60(3):512.
  • 6John Madsen, Hong Liang, Kim Lee Sim, et al. Method of produring and purifying angiostatin[P]. US 20030104525, 2003.
  • 7FolkmanJ.What is the evidence that tumors are angiogenesis dependent [J].J Natl Cancer Inst,1989,82:4-4.
  • 8卢文菊,罗进贤,何建国,张添元.人血管抑素基因工程菌发酵条件的初步研究[J].广州医学院学报,2000,28(3):1-3. 被引量:6
  • 9O'Reilly MS, Boehm T, Shing Y, et al. Angiostatin:an novel angiogenesis inhibitor that mediates the suppression of metastases by a lesis lung carcinoma[J]. Cell, 1994, 79(1) :315.

二级参考文献19

  • 1张涛铸,谢幸殊,张嗣良,叶勤.γ干扰素工程菌发酵工艺研究[J].华东化工学院学报,1993,19(2):153-158. 被引量:2
  • 2Yee L,Biotech Lett,1993年,15卷,971页
  • 3Han K,Biotechnology Bioengineering,1992年,39卷,663页
  • 4Jin S D,J Fenment Bioeng,1992年,74卷,3期,196页
  • 5Seo D J,J Ferment Bioeng,1992年,74卷,196页
  • 6Lee J H,Biotech Lett,1989年,11卷,695页
  • 7Lee C W,Enzyme Microb Technol,1989年,11卷,49页
  • 8Pan J G,Biotech Lett,1987年,9卷,89页
  • 9杨如燕,工业微生物,1998年,28卷,3期,30页
  • 10吴梧桐,基因工程药物,1996年

共引文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部